Home › Funds › ING GROEP NV › ABT
ING GROEP NV position in ABT
ABBOTT LABORATORIES · Health Care
ING GROEP NV reported holding 1,320,415 shares of ABT (ABBOTT LABORATORIES) in its Q2 2026 13F filing — a position valued at US$119.8M, representing 0.59% of its reported portfolio and ranking #33 among its reported holdings. ING GROEP NV has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ING GROEP NV's ABT position evolved
ING GROEP NV first disclosed a stake in ABT in Q3 2023 at 968,113 shares (US$93.8M). The position peaked in Q2 2026 at 1,320,415 shares, worth US$119.8M. Across 12 filings, ING GROEP NV increased the stake 8 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,320,415 shares valued at US$119.8M — an increase of 299,525 shares quarter over quarter.. Notable position changes include a 150% increase in Q1 2025 (shares rose 3% over the following quarter), a 88% trim in Q2 2025 (shares fell 1% over the following quarter), a 331% increase in Q3 2025 (shares fell 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 968.11K | $93.76M | New |
| Q4 2023 | 272.68K | $30.01M | Reduce |
| Q1 2024 | 277.39K | $31.53M | Add |
| Q2 2024 | 429.80K | $44.66M | Add |
| Q3 2024 | 452.79K | $51.62M | Add |
| Q4 2024 | 353.67K | $40.00M | Reduce |
| Q1 2025 | 882.74K | $117.10M | Add |
| Q2 2025 | 109.88K | $14.94M | Reduce |
| Q3 2025 | 473.38K | $63.40M | Add |
| Q4 2025 | 595.44K | $74.60M | Add |
| Q1 2026 | 1.02M | $104.81M | Add |
| Q2 2026 | 1.32M | $119.81M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Sixth Street Partners Management Company, L.P. 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital International Investors 34.65M sh · $3.15B · Q2 2026
- Deutsche Bank AG 16.71M sh · $1.52B · Q2 2026
More on ING GROEP NV
FAQ
How long has ING GROEP NV held ABT?
ING GROEP NV has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is ING GROEP NV's current position in ABT?
As of Q2 2026, ING GROEP NV holds 1.32M shares of ABT (ABBOTT LABORATORIES), valued at $119.81M, representing 0.59% of its reported portfolio and ranking #33.
Has ING GROEP NV been buying or selling ABT?
In the latest 13F filing (Q2 2026), ING GROEP NV increased its position in ABT. The position peaked in Q2 2026 at 1.32M shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.